Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novocure Ltd Ord Sh (NQ: NVCR )

57.17 +0.36 (+0.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 563,923
Open 56.35
Bid (Size) 57.25 (1)
Ask (Size) 59.01 (1)
Prev. Close 56.81
Today's Range 56.05 - 57.64
52wk Range 56.05 - 120.03
Shares Outstanding 103,647,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2023
 
Via Benzinga
What 4 Analyst Ratings Have To Say About NovoCure
 
Via Benzinga

Performance

YTD
-15.85%
-15.85%
1 Month
-26.98%
-26.98%
3 Month
-16.98%
-16.98%
6 Month
-22.36%
-22.36%
1 Year
-28.64%
-28.64%

More News

Read More
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
From Novocure
Via Business Wire
2 Best Defensive Stocks to Buy in March
Via The Motley Fool
NovoCure Earnings Perspective: Return On Capital Employed
Via Benzinga
Why NovoCure Stock Is Falling Today
Via The Motley Fool
2 Stocks That Could Rebound and Rise 30% or More in 2023
Via The Motley Fool
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
From Novocure
Via Business Wire
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
NovoCure (NVCR) Q4 2022 Earnings Call Transcript
Via The Motley Fool
Why Novocure Stock Was so Healthy Today
Via The Motley Fool
Why Novocure Stock Is Sliding Today
Via The Motley Fool
Will Novocure Stock Sink or Soar in 2023?
Via The Motley Fool
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
From Novocure
Via Business Wire
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
From Novocure
Via Business Wire
Novocure Round-Trips Its Recent Breakout After Announcing A Series Of C-Suite Changes
Via Investor's Business Daily
Why Novocure Stock Is Sinking Today
Via The Motley Fool
Earnings Scheduled For February 23, 2023
Via Benzinga
Novocure Announces Organizational Changes to Prepare for Future Growth
From Novocure
Via Business Wire
Novocure Has Fallen More Than 20% Over Seven Days — Why It Fell From Grace
Via Investor's Business Daily
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
From Novocure
Via Business Wire
Is NovoCure a Good Stock to Buy Right Now?
Via The Motley Fool
Stock Market Mostly Higher Amid Jobs Report; Tesla Price Cuts, GE Spinoff In Focus: Weekly Review
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.